JAZZ
USDJazz Pharmaceuticals plc Common Stock (Ireland)
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$110.945
Kõrge
$111.450
Madal
$109.480
Maht
0.48M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
6.6B
Tööstusharu
Biotehnoloogia
Riik
Ireland
Kauplemisstatistika
Keskmine maht
1.27M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $202 Price Target
Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals with a Buy and maintains $202 price target.
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug...
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced late-breaking Phase 4 data evaluating treatment benefits of Xywav® (calcium, magnesium,...
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $202 Price Target
Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals with a Buy and maintains $202 price target.
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 IMforte study of Zepzelca® (lurbinectedin) in combination...
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term data, including the first report of median overall survival (OS) from the Phase 2...
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nineteen abstracts, including eleven late-breaking abstracts will be presented at SLEEP...
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.